Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 8, 2017, Pages 1942-1950

  Zhong, Jiu Chang ^a,b   Zhang, Zhen Zhou ^a,b   Wang, Wang ^c   McKinnie, Shaun M K ^c   Vederas, John C ^c   Oudit, Gavin Y ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute of Hypertension   (China)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Apelin; Apelin analogue; Apelin receptor; Heart failure; Vascular disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APELIN; APELIN DERIVATIVE; APELIN RECEPTOR; APELIN RECEPTOR AGONIST; OPIATE AGONIST; PEPTIDE DERIVATIVE; RECOMBINANT APELIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; APLN PROTEIN, HUMAN; APLN PROTEIN, MOUSE; APLNR PROTEIN, HUMAN; APLNR PROTEIN, MOUSE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG MECHANISM; HEART DISEASE; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INOTROPISM; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTEIN TARGETING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASODILATATION; AGONISTS; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ENERGY METABOLISM; GENETICS; HEART CONTRACTION; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; APELIN; APELIN RECEPTORS; CARDIOVASCULAR DISEASES; ENERGY METABOLISM; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION;

EID: 85006511767     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.11.007     Document Type: Article

References (130)

1. Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M.X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., Kurokawa, T., Onda, H., Fujino, M., Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251 (1998), 471–476.
2. Folino, A., Montarolo, P.G., Samaja, M., Rastaldo, R., Effects of apelin on the cardiovascular system. Heart Fail. Rev. 20 (2015), 505–518.
3. Chapman, N.A., Dupre, D.J., Rainey, J.K., The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochem. Cell Biol. 92 (2014), 431–440.
4. Wang, W., McKinnie, S.M., Patel, V.B., Haddad, G., Wang, Z., Zhabyeyev, P., Das, S.K., Basu, R., McLean, B., Kandalam, V., Penninger, J.M., Kassiri, Z., Vederas, J.C., Murray, A.G., Oudit, G.Y., Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues. J. Am. Heart Assoc., 2, 2013, e000249.
5. Chen, L.J., Xu, R., Yu, H.M., Chang, Q., Zhong, J.C., The ACE2/apelin signaling, MicroRNAs, and hypertension. Int. J. Hypertens., 2015, 2015, 896861.
6. O'Carroll, A.M., Lolait, S.J., Harris, L.E., Pope, G.R., The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J. Endocrinol. 219 (2013), R13–R35.
7. Zhou, Q., Cao, J., Chen, L., Apelin/APJ system: a novel therapeutic target for oxidative stress-related inflammatory diseases (Review). Int. J. Mol. Med. 37 (2016), 1159–1169.
8. Yang, P., Maguire, J.J., Davenport, A.P., Apelin, elabela/toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol. Sci. 36 (2015), 560–567.
9. Perjes, A., Kilpio, T., Ulvila, J., Magga, J., Alakoski, T., Szabo, Z., Vainio, L., Halmetoja, E., Vuolteenaho, O., Petaja-Repo, U., Szokodi, I., Kerkela, R., Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res. Cardiol., 111, 2016, 2.
10. Chng, S.C., Ho, L., Tian, J., Reversade, B., ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev. Cell 27 (2013), 672–680.
11. Yamaleyeva, L.M., Shaltout, H.A., Varagic, J., Apelin-13 in blood pressure regulation and cardiovascular disease. Curr. Opin. Nephrol. Hypertens., 2016.
12. Pitkin, S.L., Maguire, J.J., Bonner, T.I., Davenport, A.P., International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol. Rev. 62 (2010), 331–342.
13. Maguire, J.J., Kleinz, M.J., Pitkin, S.L., Davenport, A.P., [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54 (2009), 598–604.
14. Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H., Nishimura, O., Fujino, M., Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275 (2000), 21061–21067.
15. Zhen, E.Y., Higgs, R.E., Gutierrez, J.A., Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Anal. Biochem. 442 (2013), 1–9.
16. Lee, D.K., Ferguson, S.S., George, S.R., O'Dowd, B.F., The fate of the internalized apelin receptor is determined by different isoforms of apelin mediating differential interaction with beta-arrestin. Biochem. Biophys. Res. Commun. 395 (2010), 185–189.
17. Kleinz, M.J., Skepper, J.N., Davenport, A.P., Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul. Pept. 126 (2005), 233–240.
18. Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigne, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpene, C., Audigier, Y., Saulnier-Blache, J.S., Valet, P., Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146 (2005), 1764–1771.
19. Japp, A.G., Cruden, N.L., Amer, D.A., Li, V.K., Goudie, E.B., Johnston, N.R., Sharma, S., Neilson, I., Webb, D.J., Megson, I.L., Flapan, A.D., Newby, D.E., Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 52 (2008), 908–913.
20. Wang, W., McKinnie, S.M., Farhan, M., Paul, M., McDonald, T., McLean, B., Llorens-Cortes, C., Hazra, S., Murray, A.G., Vederas, J.C., Oudit, G.Y., Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system. Hypertension, 2016.
21. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A., Tummino, P., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277 (2002), 14838–14843.
22. Zhong, J., Basu, R., Guo, D., Chow, F.L., Byrns, S., Schuster, M., Loibner, H., Wang, X.H., Penninger, J.M., Kassiri, Z., Oudit, G.Y., Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728 (718 p following 728).
23. Jin, H.Y., Chen, L.J., Zhang, Z.Z., Xu, Y.L., Song, B., Xu, R., Oudit, G.Y., Gao, P.J., Zhu, D.L., Zhong, J.C., Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling. J. Transl. Med., 13, 2015, 255.
24. Sato, T., Suzuki, T., Watanabe, H., Kadowaki, A., Fukamizu, A., Liu, P.P., Kimura, A., Ito, H., Penninger, J.M., Imai, Y., Kuba, K., Apelin is a positive regulator of ACE2. J. Clin. Investig. 123 (2013), 5203–5211.
25. Barnes, G., Japp, A.G., Newby, D.E., Translational promise of the apelin–APJ system. Heart 96 (2010), 1011–1016.
26. Iturrioz, X., Alvear-Perez, R., De Mota, N., Franchet, C., Guillier, F., Leroux, V., Dabire, H., Le Jouan, M., Chabane, H., Gerbier, R., Bonnet, D., Berdeaux, A., Maigret, B., Galzi, J.L., Hibert, M., Llorens-Cortes, C., Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J. 24 (2010), 1506–1517.
27. Ceraudo, E., Galanth, C., Carpentier, E., Banegas-Font, I., Schonegge, A.M., Alvear-Perez, R., Iturrioz, X., Bouvier, M., Llorens-Cortes, C., Biased signaling favoring gi over beta-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine. J. Biol. Chem. 289 (2014), 24599–24610.
28. El Messari, S., Iturrioz, X., Fassot, C., De Mota, N., Roesch, D., Llorens-Cortes, C., Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. J. Neurochem. 90 (2004), 1290–1301.
29. Lee, D.K., Saldivia, V.R., Nguyen, T., Cheng, R., George, S.R., O'Dowd, B.F., Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 146 (2005), 231–236.
30. Medhurst, A.D., Jennings, C.A., Robbins, M.J., Davis, R.P., Ellis, C., Winborn, K.Y., Lawrie, K.W., Hervieu, G., Riley, G., Bolaky, J.E., Herrity, N.C., Murdock, P., Darker, J.G., Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J. Neurochem. 84 (2003), 1162–1172.
31. Gerbier, R., Leroux, V., Couvineau, P., Alvear-Perez, R., Maigret, B., Llorens-Cortes, C., Iturrioz, X., New structural insights into the apelin receptor: identification of key residues for apelin binding. FASEB J. 29 (2015), 314–322.
32. McKinnie, S.M., Fischer, C., Tran, K.M., Wang, W., Mosquera, F., Oudit, G.Y., Vederas, J.C., The metalloprotease neprilysin degrades and inactivates apelin peptides. Chembiochem, 2016.
33. Han, X., Zhang, D.L., Yin, D.X., Zhang, Q.D., Liu, W.H., Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA. Can. J. Physiol. Pharmacol. 91 (2013), 708–714.
34. Lee, D.K., Cheng, R., Nguyen, T., Fan, T., Kariyawasam, A.P., Liu, Y., Osmond, D.H., George, S.R., O'Dowd, B.F., Characterization of apelin, the ligand for the APJ receptor. J. Neurochem. 74 (2000), 34–41.
35. Najafipour, H., Soltani Hekmat, A., Nekooian, A.A., Esmaeili-Mahani, S., Apelin receptor expression in ischemic and non-ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats. Regul. Pept. 178 (2012), 43–50.
36. Akcilar, R., Turgut, S., Caner, V., Akcilar, A., Ayada, C., Elmas, L., Ozcan, T.O., Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clin. Exp. Hypertens. 35 (2013), 550–557.
37. Saint-Geniez, M., Masri, B., Malecaze, F., Knibiehler, B., Audigier, Y., Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech. Dev. 110 (2002), 183–186.
38. Cooke, J.P., Losordo, D.W., Nitric oxide and angiogenesis. Circulation 105 (2002), 2133–2135.
39. Yang, X., Zhu, W., Zhang, P., Chen, K., Zhao, L., Li, J., Wei, M., Liu, M., Apelin-13 stimulates angiogenesis by promoting crosstalk between AMP-activated protein kinase and Akt signaling in myocardial microvascular endothelial cells. Mol. Med. Rep. 9 (2014), 1590–1596.
40. Bai, B., Cai, X., Jiang, Y., Karteris, E., Chen, J., Heterodimerization of apelin receptor and neurotensin receptor 1 induces phosphorylation of ERK(1/2) and cell proliferation via Galphaq-mediated mechanism. J. Cell. Mol. Med. 18 (2014), 2071–2081.
41. Alastalo, T.P., Li, M., Perez Vde, J., Pham, D., Sawada, H., Wang, J.K., Koskenvuo, M., Wang, L., Freeman, B.A., Chang, H.Y., Rabinovitch, M., Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J. Clin. Invest. 121 (2011), 3735–3746.
42. Japp, A.G., Cruden, N.L., Barnes, G., van Gemeren, N., Mathews, J., Adamson, J., Johnston, N.R., Denvir, M.A., Megson, I.L., Flapan, A.D., Newby, D.E., Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121 (2010), 1818–1827.
43. Wang, I.N., Wang, X., Ge, X., Anderson, J., Ho, M., Ashley, E., Liu, J., Butte, M.J., Yazawa, M., Dolmetsch, R.E., Quertermous, T., Yang, P.C., Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells. PLoS One, 7, 2012, e38328.
44. Inui, M., Fukui, A., Ito, Y., Asashima, M., Xapelin and Xmsr are required for cardiovascular development in Xenopus laevis. Dev. Biol. 298 (2006), 188–200.
45. Takakura, N., Kidoya, H., Maturation of blood vessels by haematopoietic stem cells and progenitor cells: involvement of apelin/APJ and angiopoietin/Tie2 interactions in vessel caliber size regulation. Thromb. Haemost. 101 (2009), 999–1005.
46. Szokodi, I., Tavi, P., Foldes, G., Voutilainen-Myllyla, S., Ilves, M., Tokola, H., Pikkarainen, S., Piuhola, J., Rysa, J., Toth, M., Ruskoaho, H., Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res. 91 (2002), 434–440.
47. Chen, M.M., Ashley, E.A., Deng, D.X., Tsalenko, A., Deng, A., Tabibiazar, R., Ben-Dor, A., Fenster, B., Yang, E., King, J.Y., Fowler, M., Robbins, R., Johnson, F.L., Bruhn, L., McDonagh, T., Dargie, H., Yakhini, Z., Tsao, P.S., Quertermous, T., Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 (2003), 1432–1439.
48. Ashley, E.A., Powers, J., Chen, M., Kundu, R., Finsterbach, T., Caffarelli, A., Deng, A., Eichhorn, J., Mahajan, R., Agrawal, R., Greve, J., Robbins, R., Patterson, A.J., Bernstein, D., Quertermous, T., The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65 (2005), 73–82.
49. Charles, C.J., Rademaker, M.T., Richards, A.M., Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J. Endocrinol. 189 (2006), 701–710.
50. O'Dowd, B.F., Heiber, M., Chan, A., Heng, H.H., Tsui, L.C., Kennedy, J.L., Shi, X., Petronis, A., George, S.R., Nguyen, T., A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136 (1993), 355–360.
51. Siddiquee, K., Hampton, J., McAnally, D., May, L., Smith, L., The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br. J. Pharmacol. 168 (2013), 1104–1117.
52. Patel, V.B., Zhong, J.C., Grant, M.B., Oudit, G.Y., Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ. Res. 118 (2016), 1313–1326.
53. Zhong, J.C., Yu, X.Y., Huang, Y., Yung, L.M., Lau, C.W., Lin, S.G., Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc. Res. 74 (2007), 388–395.
54. Ishida, J., Hashimoto, T., Hashimoto, Y., Nishiwaki, S., Iguchi, T., Harada, S., Sugaya, T., Matsuzaki, H., Yamamoto, R., Shiota, N., Okunishi, H., Kihara, M., Umemura, S., Sugiyama, F., Yagami, K., Kasuya, Y., Mochizuki, N., Fukamizu, A., Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J. Biol. Chem. 279 (2004), 26274–26279.
55. Zhang, J., Gu, C., Noble, N.A., Border, W.A., Huang, Y., Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. Am. J. Physiol. Ren. Physiol. 301 (2011), F723–F732.
56. Charo, D.N., Ho, M., Fajardo, G., Kawana, M., Kundu, R.K., Sheikh, A.Y., Finsterbach, T.P., Leeper, N.J., Ernst, K.V., Chen, M.M., Ho, Y.D., Chun, H.J., Bernstein, D., Ashley, E.A., Quertermous, T., Endogenous regulation of cardiovascular function by apelin-APJ. Am. J. Physiol. Heart Circ. Physiol. 297 (2009), H1904–H1913.
57. Farkasfalvi, K., Stagg, M.A., Coppen, S.R., Siedlecka, U., Lee, J., Soppa, G.K., Marczin, N., Szokodi, I., Yacoub, M.H., Terracciano, C.M., Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem. Biophys. Res. Commun. 357 (2007), 889–895.
58. Zhou, Y., Deng, L., Zhao, D., Chen, L., Yao, Z., Guo, X., Liu, X., Lv, L., Leng, B., Xu, W., Qiao, G., Shan, H., MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting Apelin-13. J. Cell. Mol. Med. 20 (2016), 495–505.
59. Yuan, Z.-s., Zhou, Y.-z., Liao, X.-b., Luo, J.-w., Shen, K.-j., Hu, Y.-r., Gu, L., Li, J.-m., Tan, C.-m., Chen, H.-m., Zhou, X.-m., Apelin attenuates the osteoblastic differentiation of aortic valve interstitial cells via the ERK and PI3-K/Akt pathways. Amino Acids 47 (2015), 2475–2482.
60. Zhang, F., Sun, H.J., Xiong, X.Q., Chen, Q., Li, Y.H., Kang, Y.M., Wang, J.J., Gao, X.Y., Zhu, G.Q., Apelin-13 and APJ in paraventricular nucleus contribute to hypertension via sympathetic activation and vasopressin release in spontaneously hypertensive rats. Acta Physiol. 212 (2014), 17–27.
61. Ye, L., Ding, F., Zhang, L., Shen, A., Yao, H., Deng, L., Ding, Y., Serum apelin is associated with left ventricular hypertrophy in untreated hypertension patients. J. Transl. Med., 13, 2015, 290.
62. Laflamme, M.A., Murry, C.E., Heart regeneration. Nature 473 (2011), 326–335.
63. Dalzell, J.R., Rocchiccioli, J.P., Weir, R.A., Jackson, C.E., Padmanabhan, N., Gardner, R.S., Petrie, M.C., McMurray, J.J., The emerging potential of the apelin-APJ system in heart failure. J. Card. Fail. 21 (2015), 489–498.
64. Kuba, K., Zhang, L., Imai, Y., Arab, S., Chen, M., Maekawa, Y., Leschnik, M., Leibbrandt, A., Markovic, M., Schwaighofer, J., Beetz, N., Musialek, R., Neely, G.G., Komnenovic, V., Kolm, U., Metzler, B., Ricci, R., Hara, H., Meixner, A., Nghiem, M., Chen, X., Dawood, F., Wong, K.M., Sarao, R., Cukerman, E., Kimura, A., Hein, L., Thalhammer, J., Liu, P.P., Penninger, J.M., Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload. Circ. Res. 101 (2007), e32–e42.
65. Najafipour, H., Vakili, A., Shahouzehi, B., Soltani Hekmat, A., Masoomi, Y., Yeganeh Hajahmadi, M., Esmaeli-Mahani, S., Investigation of changes in apelin receptor mRNA and protein expression in the myocardium and aorta of rats with two-kidney, one-clip (2K1C) Goldblatt hypertension. J. Physiol. Biochem. 71 (2015), 165–175.
66. Pang, H., Han, B., Yu, T., Zong, Z., Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure. Int. J. Mol. Med. 34 (2014), 756–764.
67. Koguchi, W., Kobayashi, N., Takeshima, H., Ishikawa, M., Sugiyama, F., Ishimitsu, T., Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ. J. 76 (2012), 137–144.
68. Perjes, A., Skoumal, R., Tenhunen, O., Konyi, A., Simon, M., Horvath, I.G., Kerkela, R., Ruskoaho, H., Szokodi, I., Apelin increases cardiac contractility via protein kinase cepsilon- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One, 9, 2014, e93473.
69. Murata, K., Ishida, J., Ishimaru, T., Mizukami, H., Hamada, J., Saito, C., Fukamizu, A., Lactation is a risk factor of postpartum heart failure in mice with cardiomyocyte-specific apelin receptor (APJ) overexpression. J. Biol. Chem. 291 (2016), 11241–11251.
70. Barnes, G.D., Alam, S., Carter, G., Pedersen, C.M., Lee, K.M., Hubbard, T.J., Veitch, S., Jeong, H., White, A., Cruden, N.L., Huson, L., Japp, A.G., Newby, D.E., Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ. Heart Fail. 6 (2013), 482–491.
71. Przewlocka-Kosmala, M., Kotwica, T., Mysiak, A., Kosmala, W., Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J. Hypertens. 29 (2011), 971–979.
72. Boal, F., Roumegoux, J., Alfarano, C., Timotin, A., Calise, D., Anesia, R., Drougard, A., Knauf, C., Lagente, C., Roncalli, J., Desmoulin, F., Tronchere, H., Valet, P., Parini, A., Kunduzova, O., Apelin regulates FoxO3 translocation to mediate cardioprotective responses to myocardial injury and obesity. Sci. Rep., 5, 2015, 16104.
73. Foldes, G., Horkay, F., Szokodi, I., Vuolteenaho, O., Ilves, M., Lindstedt, K.A., Mayranpaa, M., Sarman, B., Seres, L., Skoumal, R., Lako-Futo, Z., deChatel, R., Ruskoaho, H., Toth, M., Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem. Biophys. Res. Commun. 308 (2003), 480–485.
74. Iwanaga, Y., Kihara, Y., Takenaka, H., Kita, T., Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J. Mol. Cell. Cardiol. 41 (2006), 798–806.
75. Liu, H.T., Chen, M., Yu, J., Li, W.J., Tao, L., Li, Y., Guo, W.Y., Wang, H.C., Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention. Medicine, 94, 2015, e449.
76. Sheikh, A.Y., Chun, H.J., Glassford, A.J., Kundu, R.K., Kutschka, I., Ardigo, D., Hendry, S.L., Wagner, R.A., Chen, M.M., Ali, Z.A., Yue, P., Huynh, D.T., Connolly, A.J., Pelletier, M.P., Tsao, P.S., Robbins, R.C., Quertermous, T., In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am. J. Physiol. Heart Circ. Physiol. 294 (2008), H88–H98.
77. Ustunel, I., Acar, N., Gemici, B., Ozbey, O., Edizer, I., Soylu, H., Tepekoy, F., Izgut-Uysal, V.N., The effects of water immersion and restraint stress on the expressions of apelin, apelin receptor (APJR) and apoptosis rate in the rat heart. Acta Histochem. 116 (2014), 675–681.
78. Boal, F., Timotin, A., Roumegoux, J., Alfarano, C., Calise, D., Anesia, R., Parini, A., Valet, P., Tronchere, H., Kunduzova, O., Apelin-13 administration protects against ischaemia/reperfusion-mediated apoptosis through the FoxO1 pathway in high-fat diet-induced obesity. Br. J. Pharmacol. 173 (2016), 1850–1863.
79. Zeng, H., He, X., Hou, X., Li, L., Chen, J.X., Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am. J. Physiol. Heart Circ. Physiol. 306 (2014), H585–H597.
80. Li, L., Zeng, H., Hou, X., He, X., Chen, J.X., Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction. PLoS One, 8, 2013, e71041.
81. Hou, X., Zeng, H., He, X., Chen, J.X., Sirt3 is essential for apelin-induced angiogenesis in post-myocardial infarction of diabetes. J. Cell. Mol. Med. 19 (2015), 53–61.
82. Siddiquee, K., Hampton, J., Khan, S., Zadory, D., Gleaves, L., Vaughan, D.E., Smith, L.H., Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J. Hypertens. 29 (2011), 724–731.
83. Zeng, X.J., Zhang, L.K., Wang, H.X., Lu, L.Q., Ma, L.Q., Tang, C.S., Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30 (2009), 1144–1152.
84. 2 + -ATPase and ryanodine receptor. Cardiovasc. Res. 100 (2013), 114–124.
85. Minamino, T., Kitakaze, M., ER stress in cardiovascular disease. J. Mol. Cell. Cardiol. 48 (2010), 1105–1110.
86. Tao, J., Zhu, W., Li, Y., Xin, P., Li, J., Liu, M., Li, J., Redington, A.N., Wei, M., Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am. J. Physiol. Heart Circ. Physiol. 301 (2011), H1471–H1486.
87. Busch, R., Strohbach, A., Pennewitz, M., Lorenz, F., Bahls, M., Busch, M.C., Felix, S.B., Regulation of the endothelial apelin/APJ system by hemodynamic fluid flow. Cell. Signal. 27 (2015), 1286–1296.
88. Scimia, M.C., Hurtado, C., Ray, S., Metzler, S., Wei, K., Wang, J., Woods, C.E., Purcell, N.H., Catalucci, D., Akasaka, T., Bueno, O.F., Vlasuk, G.P., Kaliman, P., Bodmer, R., Smith, L.H., Ashley, E., Mercola, M., Brown, J.H., Ruiz-Lozano, P., APJ acts as a dual receptor in cardiac hypertrophy. Nature 488 (2012), 394–398.
89. Cheng, X., Cheng, X.S., Pang, C.C., Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur. J. Pharmacol. 470 (2003), 171–175.
90. Jia, Y.X., Lu, Z.F., Zhang, J., Pan, C.S., Yang, J.H., Zhao, J., Yu, F., Duan, X.H., Tang, C.S., Qi, Y.F., Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 28 (2007), 2023–2029.
91. Gurzu, B., Petrescu, B.C., Costuleanu, M., Petrescu, G., Interactions between apelin and angiotensin II on rat portal vein. J. Renin-Angiotensin-Aldosterone Syst.: JRAAS 7 (2006), 212–216.
92. Kagiyama, S., Fukuhara, M., Matsumura, K., Lin, Y., Fujii, K., Iida, M., Central and peripheral cardiovascular actions of apelin in conscious rats. Regul. Pept. 125 (2005), 55–59.
93. Adam, F., Khatib, A.M., Lopez, J.J., Vatier, C., Turpin, S., Muscat, A., Soulet, F., Aries, A., Jardin, I., Bobe, R., Stepanian, A., de Prost, D., Dray, C., Rosado, J.A., Valet, P., Feve, B., Siegfried, G., Apelin: an antithrombotic factor that inhibits platelet function. Blood 127 (2016), 908–920.
94. Li, L., Xu, J., Chen, L., Jiang, Z., Apelin/APJ system: a novel promising therapy target for thrombotic diseases. Acta Biochim. Biophys. Sin. 48 (2016), 589–591.
95. Dutta, P., Courties, G., Wei, Y., Leuschner, F., Gorbatov, R., Robbins, C.S., Iwamoto, Y., Thompson, B., Carlson, A.L., Heidt, T., Majmudar, M.D., Lasitschka, F., Etzrodt, M., Waterman, P., Waring, M.T., Chicoine, A.T., van der Laan, A.M., Niessen, H.W., Piek, J.J., Rubin, B.B., Butany, J., Stone, J.R., Katus, H.A., Murphy, S.A., Morrow, D.A., Sabatine, M.S., Vinegoni, C., Moskowitz, M.A., Pittet, M.J., Libby, P., Lin, C.P., Swirski, F.K., Weissleder, R., Nahrendorf, M., Myocardial infarction accelerates atherosclerosis. Nature 487 (2012), 325–329.
96. Moore, K.J., Tabas, I., Macrophages in the pathogenesis of atherosclerosis. Cell 145 (2011), 341–355.
97. Zhang, Z., Chen, L., Zhong, J., Gao, P., Oudit, G.Y., ACE2/Ang-(1-7) signaling and vascular remodeling. Sci. China Life Sci. 57 (2014), 802–808.
98. Akboga, M.K., Akyel, A., Sahinarslan, A., Demirtas, C.Y., Yayla, C., Boyaci, B., Yalcin, R., Relationship between plasma apelin level and coronary collateral circulation. Atherosclerosis 235 (2014), 289–294.
99. Yao, F., Lv, Y.C., Zhang, M., Xie, W., Tan, Y.L., Gong, D., Cheng, H.P., Liu, D., Li, L., Liu, X.Y., Zheng, X.L., Tang, C.K., Apelin-13 impedes foam cell formation by activating class III PI3K/beclin-1-mediated autophagic pathway. Biochem. Biophys. Res. Commun. 466 (2015), 637–643.
100. Chun, H.J., Ali, Z.A., Kojima, Y., Kundu, R.K., Sheikh, A.Y., Agrawal, R., Zheng, L., Leeper, N.J., Pearl, N.E., Patterson, A.J., Anderson, J.P., Tsao, P.S., Lenardo, M.J., Ashley, E.A., Quertermous, T., Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J. Clin. Invest. 118 (2008), 3343–3354.
101. Kojima, Y., Kundu, R.K., Cox, C.M., Leeper, N.J., Anderson, J.A., Chun, H.J., Ali, Z.A., Ashley, E.A., Krieg, P.A., Quertermous, T., Upregulation of the apelin-APJ pathway promotes neointima formation in the carotid ligation model in mouse. Cardiovasc. Res. 87 (2010), 156–165.
102. Liang, D., Han, D., Fan, W., Zhang, R., Qiao, H., Fan, M., Su, T., Ma, S., Li, X., Chen, J., Wang, Y., Ren, J., Cao, F., Therapeutic efficacy of apelin on transplanted mesenchymal stem cells in hindlimb ischemic mice via regulation of autophagy. Sci. Rep., 6, 2016, 21914.
103. Toshner, M., Tajsic, T., Morrell, N.W., Pulmonary hypertension: advances in pathogenesis and treatment. Br. Med. Bull. 94 (2010), 21–32.
104. Goetze, J.P., Rehfeld, J.F., Carlsen, J., Videbaek, R., Andersen, C.B., Boesgaard, S., Friis-Hansen, L., Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept. 133 (2006), 134–138.
105. Kim, J., Kang, Y., Kojima, Y., Lighthouse, J.K., Hu, X., Aldred, M.A., McLean, D.L., Park, H., Comhair, S.A., Greif, D.M., Erzurum, S.C., Chun, H.J., An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat. Med. 19 (2013), 74–82.
106. Andersen, C.U., Markvardsen, L.H., Hilberg, O., Simonsen, U., Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension. Respir. Med. 103 (2009), 1663–1671.
107. Chandra, S.M., Razavi, H., Kim, J., Agrawal, R., Kundu, R.K., de Jesus Perez, V., Zamanian, R.T., Quertermous, T., Chun, H.J., Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 31 (2011), 814–820.
108. Falcao-Pires, I., Goncalves, N., Henriques-Coelho, T., Moreira-Goncalves, D., Roncon-Albuquerque, R. Jr., Leite-Moreira, A.F., Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 296 (2009), H2007–H2014.
109. Zhang, H., Gong, Y., Wang, Z., Jiang, L., Chen, R., Fan, X., Zhu, H., Han, L., Li, X., Xiao, J., Kong, X., Apelin inhibits the proliferation and migration of rat PASMCs via the activation of PI3K/Akt/mTOR signal and the inhibition of autophagy under hypoxia. J. Cell. Mol. Med. 18 (2014), 542–553.
110. Pauli, A., Norris, M.L., Valen, E., Chew, G.L., Gagnon, J.A., Zimmerman, S., Mitchell, A., Ma, J., Dubrulle, J., Reyon, D., Tsai, S.Q., Joung, J.K., Saghatelian, A., Schier, A.F., Toddler: an embryonic signal that promotes cell movement via apelin receptors. Science, 343, 2014, 1248636.
111. Tall, A.R., Yvan-Charvet, L., Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15 (2015), 104–116.
112. Margathe, J.F., Iturrioz, X., Alvear-Perez, R., Marsol, C., Riche, S., Chabane, H., Tounsi, N., Kuhry, M., Heissler, D., Hibert, M., Llorens-Cortes, C., Bonnet, D., Structure-activity relationship studies toward the discovery of selective apelin receptor agonists. J. Med. Chem. 57 (2014), 2908–2919.
113. Khan, P., Maloney, P.R., Hedrick, M., Gosalia, P., Milewski, M., Li, L., Roth, G.P., Sergienko, E., Suyama, E., Sugarman, E., Nguyen, K., Mehta, A., Vasile, S., Su, Y., Shi, S., Stonich, D., Nguyen, H., Zeng, F.Y., Novo, A.M., Vicchiarelli, M., Diwan, J., Chung, T.D.Y., Pinkerton, A.B., Smith, L.H., Functional agonists of the apelin (APJ) receptor. Probe Reports From the NIH Molecular Libraries Program, 2010, National Center for Biotechnology Information, Bethesda, MD, 1–9.
114. Hachtel, S., Wohlfart, P., Weston, J., Mueller, M., Defossa, E., Mertsch, K., Weng, J.H., Binnie, R.A., Abdul-Latif, F., Bock, W.J., Walser, A., Benzoimidazole-carboxylic Acid Amide Derivatives as APJ Receptor Modulators, in, WO2014044738 A1. 2014, 1–443.
115. Narayanan, S., Maitra, R., Deschamps, J.R., Bortoff, K., Thomas, J.B., Zhang, Y., Warner, K., Vasukuttan, V., Decker, A., Runyon, S.P., Discovery of a novel small molecule agonist scaffold for the APJ receptor. Bioorg. Med. Chem. 24 (2016), 3758–3770.
116. Narayanan, S., Harris, D.L., Maitra, R., Runyon, S.P., Regulation of the apelinergic system and its potential in cardiovascular disease: peptides and small molecules as tools for discovery. J. Med. Chem. 58 (2015), 7913–7927.
117. Fan, X., Zhou, N., Zhang, X., Mukhtar, M., Lu, Z., Fang, J., DuBois, G.C., Pomerantz, R.J., Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry 42 (2003), 10163–10168.
118. Murza, A., Parent, A., Besserer-Offroy, E., Tremblay, H., Karadereye, F., Beaudet, N., Leduc, R., Sarret, P., Marsault, E., Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. ChemMedChem 7 (2012), 318–325.
119. Langelaan, D.N., Bebbington, E.M., Reddy, T., Rainey, J.K., Structural Insight into G-protein coupled receptor binding by apelin. Biochemistry 48 (2009), 537–548.
120. Macaluso, N.J., Glen, R.C., Exploring the ‘RPRL’ motif of apelin-13 through molecular simulation and biological evaluation of cyclic peptide analogues. ChemMedChem 5 (2010), 1247–1253.
121. Murza, A., Belleville, K., Longpre, J.M., Sarret, P., Marsault, E., Stability and degradation patterns of chemically modified analogs of apelin-13 in plasma and cerebrospinal fluid. Biopolymers 101 (2014), 297–303.
122. Zhang, Y., Maitra, R., Harris, D.L., Dhungana, S., Snyder, R., Runyon, S.P., Identifying structural determinants of potency for analogs of apelin-13: integration of C-terminal truncation with structure-activity. Bioorg. Med. Chem. 22 (2014), 2992–2997.
123. Iturrioz, X., Gerbier, R., Leroux, V., Alvear-Perez, R., Maigret, B., Llorens-Cortes, C., By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization. J. Biol. Chem. 285 (2010), 32627–32637.
124. Murza, A., Besserer-Offroy, E., Cote, J., Berube, P., Longpre, J.M., Dumaine, R., Lesur, O., Auger-Messier, M., Leduc, R., Sarret, P., Marsault, E., C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action. J. Med. Chem. 58 (2015), 2431–2440.
125. Brame, A.L., Maguire, J.J., Yang, P., Dyson, A., Torella, R., Cheriyan, J., Singer, M., Glen, R.C., Wilkinson, I.B., Davenport, A.P., Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension 65 (2015), 834–840.
126. Hamada, J., Kimura, J., Ishida, J., Kohda, T., Morishita, S., Ichihara, S., Fukamizu, A., Evaluation of novel cyclic analogues of apelin. Int. J. Mol. Med. 22 (2008), 547–552.
127. Zecri, F., Golosov, A., Grosche, P., Yasoshima, K., Zhao, H., Hu, Q.Y., Imase, H., Parker, D.T., Synthetic Apelin Mimetics for the Treatment of Heart Failure. vol. US20130196899 A1, 2013.
128. Jia, Z.Q., Hou, L., Leger, A., Wu, I., Kudej, A.B., Stefano, J., Jiang, C., Pan, C.Q., Akita, G.Y., Cardiovascular effects of a PEGylated apelin. Peptides 38 (2012), 181–188.
129. McKeown, S.C., Zecri, F.J., Fortier, E., Taggart, A., Sviridenko, L., Adams, C.M., McAllister, K.H., Pin, S.S., The design and implementation of a generic lipopeptide scanning platform to enable the identification of ‘locally acting’ agonists for the apelin receptor. Bioorg. Med. Chem. Lett. 24 (2014), 4871–4875.
130. Murza, A., Sainsily, X., Coquerel, D., Cote, J., Marx, P., Besserer-Offroy, E., Longpre, J.M., Laine, J., Reversade, B., Salvail, D., Leduc, R., Dumaine, R., Lesur, O., Auger-Messier, M., Sarret, P., Marsault, E., Discovery and structure-activity relationship of a bioactive fragment of elabela that modulates vascular and cardiac functions. J. Med. Chem. 59 (2016), 2962–2972.